Hepatitis B surface antigen seroclearance after nucleos(t) ide analogue discontinuation in non-cirrhotic patients with chronic hepatitis B
Hepatology Forum · 2026 · 7 (4) · 337-344
DOI: 10.14744/hf.2026.12274 ↗Abstract
Background and Aim: This study aimed to evaluate the clinical outcomes following the discontinuation of nucleos(t)ide analogue (NA) treatment in hepatitis B e antigen (HBeAg)-negative patients with chronic hepatitis B (CHB). Materials and Methods: This single-center retrospective cohort study included 146 non-cirrhotic patients with CHB who achieved long-term viral suppression under NA treatment. Seventy-three patients discontinued NA treatment, while a historical age- and sex-matched control group consisted of 73 patients who continued NA treatment. Results: Hepatitis B surface antigen (HBsAg) seroclearance occurred in eight patients (11%) in the treatment-discontinuation group, while none was observed in the treatment-contin-ued group (p = 0.004). The cumulative probability of HBsAg loss was 16.9% at month 120 after NA discontinuation. Firth-penalized Cox regression analysis identified younger age (
EUVIMED